More Videos
|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- The Rising Mountain of Debt May Be the Next Crisis
- SEC May Reinstate Rules for Short-Selling Stocks
- Latvian Banker Taking Souls as Collateral
- The Worst Expected 2010 State Budget Gaps
- Alaska Governor Sarah Palin Will Resign
- Malaysia PM Speaks to CNBC
- Cuddle Parties Heat Up
- Charting Gold & Crude Oil
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
- Top Videos: From the Black Swan to the Bond King
- Property Tax Appeals Take Toll on Governments
- Obama Plan Would Trim Back Financial Powerhouses
- Schwarzenegger Signals Key Budget Concession
- Car Dealer Determined To Fight Chrysler Over Franchise
- For Banks, Wads of Cash and Loads of Trouble
- Biden: 'We Misread How Bad The Economy Was'
- The Rising Mountain of Debt May Be the Next Crisis
- For Australian Winemakers, More Turns Out to Be Less
- Top Videos: From the Black Swan to the Bond King
RSS FEED
Text Size 
 |
AP |
According to the "National Changing Diabetes Program" which is sponsored by NVO, the "widely accepted" figure has been $174 billion. But Novo [NVO
Loading...
()
] commissioned The Lewin Group, a pharma consulting group, to broaden things out for what it's calling "The National Diabetes Economic Barometer." And all in, the study says a more accurate number for U.S. diabetes care and lost productivity in 2007 is $217.5 billion.
The report factors in an estimated additional $18 billion spent on treating more than six million Americans who don't know they have diabetes, $25 billion to take care of 57 million people with what's known as pre-diabetes, and $623 million on 180,000 pregnant women who got gestational diabetes.
Novo Nordisk has filed for Food and Drug Administration approval of a new type of once-a-day injectable diabetes drug. It's expected to get reviewed by an advisory committee next March. That's an outside panel of experts that recommends to the agency whether it should approve a drug. The FDA usually, but not always, follows the advice of such committees. Word is if it's approved NVO would call the drug "Victoza" for commercial purposes.
Is it too close to "victory" as in winning the battle against diabetes? I'm almost certain that if that's the brand name Novo wants that the FDA will scrutinize it. For now it's known by the mouthful liraglutide (lur-rag-loo-tide). If the drug comes to market it would compete against the twice-a-day injectable Byetta from Amylin Pharmaceuticals [AMLN
Loading...
()
] and the Januvia pill from Merck [MRK
Loading...
()
] . AMLN and its partners Eli Lilly [LLY
Loading...
()
] and Alkermes [ALKS
Loading...
()
] are also hoping to one-up NVO with a once-a-week version of Byetta, but the fate and timeline of that product is uncertain.
Some public health experts and advocates argue that new drugs aren't the solution to the fast-growing diabetes epidemic. They believe we need to move "upstream" with better education, eating and exercise habits and earlier diagnosis. Easier said than done.
Update: Novo Nordisk just issued this press release that the FDA advisory committee meeting on liraglutide has been postponed from March 2nd to April 2nd or 3rd. So, that means the potential FDA approval of the drug likely gets pushed into next year even further.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes